Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;57(2):347-360.
doi: 10.1002/ppul.25459. Epub 2021 May 25.

Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation

Nicholas J Antos  1   2 , Adrienne P Savant  3   4
Affiliations
Review

Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation

Nicholas J Antos et al. Pediatr Pulmonol. 2022 Feb.

Abstract

The outlook for those with cystic fibrosis (CF) has never been brighter with ever increasing life expectancy and the approval of the highly effective CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor. With that being said, the progressive pulmonary decline and importance of lung health, infection, and inflammation in CF remains. This review is the second part in a three-part CF Year in Review 2020. Part one focused on the literature related to CFTR modulators while part three will feature the multisystem effects related to CF. This review focuses on articles from Pediatric Pulmonology, including articles from other journals that are of particular interest to clinicians. Herein, we highlight studies published during 2020 related to CF pulmonary disease, infection, treatment, and diagnostics.

Keywords: clinical trials; cystic fibrosis; epidemiology; pulmonary function testing; respiratory technology.

PubMed Disclaimer

References

REFERENCES

    1. Cystic Fibrosis Foundation Patient Registry. 2019 Annual Data Report. 2020. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-...
    1. Filbrun AG, Enochs C, Caverly L, et al. Quality improvement initiative to improve pulmonary function in pediatric cystic fibrosis patients. Pediatr Pulmonol. 2020;55:3039-3045.
    1. Vandenbroucke NJ, Zampoli M, Morrow B. Lung function determinants and mortality of children and adolescents with cystic fibrosis in South Africa 2007-2016. Pediatr Pulmonol. 2020;55:1381-1387.
    1. Oates GR, Baker E, Rowe SM, et al. Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis. J Cyst Fibros. 2020;19:783-790.
    1. Leung GJ, Cho TJ, Kovesi T, Hamid JS, Radhakrishnan D. Variation in lung function and nutritional decline in cystic fibrosis by genotype: an analysis of the Canadian cystic fibrosis registry. J Cyst Fibros. 2020;19:255-261.

Substances

LinkOut - more resources